Imidazole propionate is a driver and therapeutic target in atherosclerosis [scRNA-seq]
Atherosclerosis is the main underlying cause of cardiovascular diseases (CVDs). Its prevention is based on traditional cardiovascular risk factor-based scores but often fails to identify individuals at early stages of the disease. Here, we identified microbially produced imidazole propionate (ImP) as an early biomarker of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration induced atherosclerosis without altering lipid metabolism and it was associated with activation of both systemic and local innate and adaptive immunity and inflammation. Here, we used single-cell RNA-seq to characterize the local changes of aorta-derived cells in mice under treatment with ImP for 4 and 8 weeks. Notably, ImP caused atherosclerosis through the Imidazoline-1 receptor (I1R), and the blockade of the ImP/I1R axis inhibited the development of atherosclerosis induced by ImP as well as by high cholesterol diet in mice. Identification of ImP as an early biomarker for atherosclerosis and uncovering the contribution of the ImP/I1R axis in disease progression open new avenues to improve atherosclerosis early diagnosis and therapy. Overall design: Gene expression profile at the single-cell level of aorta-derived cells from ApoE-/- mice treated (or not) with ImP (400µg/mouse/day) for 4 or 8 weeks in the drinking water and under chow diet. Two biological replicates (each a pool of 3 mice) for each experimental condition were analyzed. Multiplexing was done using CMO tags fpr single-cell RNA-seq protocol from 10x Genomics.